Evgen Pharma Share Discussion Threads

[bumpa33] 13/5/2020 11:33

Finncap, the house, have been bidding consistently on this for the last couple of weeks, they’re advertising all the business, albeit volume has dried up recently. They’re being cute about it too - moving on and off the RSP but staying on the bid. To what end I don’t know.

[toffeeman] 12/5/2020 18:30

If it doesn't close that gap.....

[moneymunch] 12/5/2020 16:55

ps the chart couldn't look more primed for the next significant move North....Fingers crossed;-)

[moneymunch] 12/5/2020 16:54

It does seem that way mesquida, along with the impatient there must be a few selling because of the selling, expecting a fall in sp, and there must be a few waiting to invest who are expecting a drop before they invest, MM's appear to be happy to accumulate at the top without dropping the share price that might in turn encourage buyers!!!??? Perhaps they know more than we do, they usually do...;-)

[mesquida] 12/5/2020 15:37

Yes, i would agree , moneymunch, the market makers have a perfect opportunity to shake a few loose holders out but so far they have seemed reluctant to do so. On the contrary, they seem quite happy to absorb sales, makes you wonder !

[moneymunch] 12/5/2020 13:29

Lol,patiently awaiting news on new CEO and/or update on proceedings, meanwhile the share price appears to be holding exceedingly well in anticipation. Gl :-)

[toffeeman] 12/5/2020 11:38

Just posting to see if this unfreezes my view of the thread.

Nowt happening atm

[moneymunch] 09/5/2020 09:37

Of course it's priced in, but we're awaiting an update on proceedings which isn't priced in, along with confirmation of new CEO and other updates on the rest of their pipeline which potentially could also include Covid-19, or even a a commercial JV to take SFX-01 to the next phase of development in anyone of their disease targets in evaluation. Gl ;-)


30/4/20

"The Company remains committed to developing sulforaphane-based medicines for the treatment of breast cancer and multiple other diseases and continues to collaborate with its various hospital and university partners."

29/1/20





.............

Targeting STAT3

SFX-01 is inspired by a natural compound which is found in cruciferous vegetables such as rocket, broccoli and kale.

In a recent clinical trial, called STEM, it was found to delay the disease getting worse in women with secondary breast cancer whose disease had already developed resistance to hormone therapy. In the trial, 25% of participants benefitted from the addition of SFX-01 to hormone therapy, but the reason this worked wasn’t known until now.

In this new research, the team found that SFX-01 blocks an important chain of reactions, called the STAT3 signalling pathway, in breast cancer cells. As a result, it reduced the ability of breast cancer cells to form tumours in mice.

The detailed understanding of how this drug works will now allow researchers to find when it’s most effective. They hope that in future it could be added to hormone therapies from the outset of treatment to increase their effectiveness in women with primary breast cancer.

Co-author Dr Bruno Simões, Research Fellow at the University of Manchester, further explained their findings:

‘We are excited by our findings that combining standard hormone therapies with SFX-01 could improve treatment of some breast cancer patients by reversing resistance driven by the STAT3 signalling pathway.’

Simon added: ‘This important discovery reveals exactly how SFX-01 can help overcome hormone therapy resistance. We hope it could now open the door to it being used from the outset of treatment, to prevent resistance from developing in the first place.’
Fine-tuning the results

Using these findings, the researchers’ next steps are to understand why some people’s tumours are more sensitive to SFX-01. They also want to know if looking at the activity of the STAT3 signalling pathway could provide a new test to determine who would benefit the most from the new drug.

‘With the success of the recent clinical trial in secondary breast cancer, we hope that further studies will now help to identify which patients may benefit the most from this drug so that it could soon reach the clinic,’ said Bruno.

Simon added: ‘We look forward to results of further trials to fully understand who is likely to benefit most and at what stage of treatment it should be added to hormone therapy to give patients the best chance of survival.’

This study was presented at the UKIBCS.

[mesquida] 08/5/2020 08:04

Thanks for that money munch, but which newspaper/magazine did it appear in. I note that the article is dated 29th January, so one could argue that it is already in the price, but nevertheless it is good background information for anybody invested here.

[moneymunch] 08/5/2020 07:40

Broccoli-based' drug could help treat breast cancer

29 January 2020


A new drug based on a compound found in cruciferous vegetables could improve the effectiveness of breast cancer hormone therapies, new research suggests.


Scientists at the University of Manchester found that the drug SFX-01 could reverse or potentially prevent resistance to hormone therapies by blocking a chain of reactions within cancer cells known as STAT3.

Up to 80% of breast cancer cases are known as oestrogen receptor (ER) positive breast cancer, since the disease’s growth is encouraged by the oestrogen hormone.

Hormone therapy can be very effective in reducing the risk of recurrence, though it’s thought around a third of patients with ER positive breast cancer see their disease return within 15 years, with some cases being attributable to patients developing resistance to treatment.

The team in Manchester assessed how SFX-01 worked by itself, as well as in combination with the hormone therapies tamoxifen and fulvestrant. The drug was tested both in patient samples and mice to see how it can be used to treat breast cancer. They found that SFX-01 reduced the ability of breast cancer stem cells to form tumours in mice, while also reducing the ability of breast cancer cells to form secondary tumours in the mice’s lungs.

The researchers also examined gene activity levels within the breast cancer stem cells from hormone therapy-resistant tumour samples from patients, discovering how cancer stem cells relied heavily on the STAT3 signalling pathway. STAT3 is able to become active when hormone therapy is used and ultimately lead to treatment resistance. However, the researchers discovered that SFX-01 was able to block the STAT3 signalling pathway and reverse the effects that may lead to hormone therapy resistance.

The drug - developed by UK company Evgen Pharma - has previously shown promise in a phase II trial as a treatment for secondary breast cancer that is already resistant to hormone therapy. That trial showed that SFX-01 was able to delay the progression of incurable secondary breast cancer in women who had already developed resistance to hormone therapy.

The drug was inspired by the natural compound sulforaphane, which is abundant in vegetables such as rocket, broccoli and kale.

The scientists in Manchester now hope that the drug could be added tamoxifen or aromatase inhibitors to increase those drugs’ effectiveness in patients with primary breast cancer. More so, the team hopes that SFX-01 could be used as a new option to treat secondary breast cancer.

The study results were presented at the UK Interdisciplinary Breast Cancer Symposium, hosted by the charity, Breast Cancer Now, in Birmingham.

Co-author of the study Dr Bruno Simões, research fellow at the University of Manchester, said: “Oestrogen receptor positive breast cancer is the most common breast cancer. These cancers frequently develop resistance to hormone therapies, which is a major clinical problem that we are working to address.

“We are excited by our findings that combining standard hormone therapies with SFX-01 could improve treatment of some breast cancer patients by reversing resistance driven by the STAT3 signalling pathway.

“With the success of the recent clinical trial in secondary breast cancer, we hope that further studies will now help to identify which patients may benefit the most from this drug so that it could soon reach the clinic.”

Dr Simon Vincent, director of Research at Breast Cancer Now, which helped to fund the study, said: “It’s really exciting that SFX-01 could in future help to improve the effectiveness of hormone therapies and prevent or treat the return of breast cancer. While hormone therapy is effective for most women, around a third still see their breast cancer return and we urgently need to find new ways to tackle and prevent drug resistance.

“This important discovery reveals exactly how SFX-01 can help overcome hormone therapy resistance and we hope it could now open the door to it being used from the outset of treatment, to prevent resistance from developing in the first place.”

[moneymunch] 07/5/2020 22:07

Thanks macmuck, and yes of course, feel free. Gl :-)

[macmuck] 07/5/2020 19:42

Cheers MM. Just dipped in a small toe.
Do you want me to repeat your post above 1647 to a couple of telegram groups I am in!
It's an excellent overview!

[moneymunch] 05/5/2020 22:08

Cheers peanut, I've been accumulating for the last few weeks and EVG still feels like it's under the radar, yet the share price continues to push North which suggests that some good news could be coming this way. It was a surprise to see the instant resignation of the CEO which would normally be extremely negative for most stocks, yet apart from the briefest of dips, the market appears completely unconcerned, and so the new CEO could have a very positive impact on share price when confirmed and development update news must be close, including SFX-01's potential for Covid-19 which seems more than obvious the more you look, and if confirmed could add significant value and see the share price re-rate substantially as witnessed in many other Bio stocks at the moment. Exciting times ahead with any luck. All the Best.;-)

[peanut100] 05/5/2020 21:48

Good posts MM thanks

[moneymunch] 05/5/2020 20:29

News expected soon on new CEO, and updates on existing and new developments could drop at anytime, including the high chance of SFX-01 evaluation for Covid-19 imho. Gla Holders ;-)

5/12/19

Memorandum of Understanding with The University of Dundee

Evgen Pharma (AIM: EVG) a clinical stage drug development company focused on the treatment of cancer and neurological conditions, announces it has entered into a Memorandum of Understanding with the The University of Dundee ("The University") to advance SFX-01 towards a clinical trial in non-alcoholic steatohepatitis ("NASH") and liver fibrosis. Evgen has agreed to supply SFX-01 to support a potential future clinical trial led by John Dillon, Professor of Hepatology and Gastrenterology in the University's School of Medicine.

John Dillon, Professor of Hepatology and Gastrenterology at the University of Dundee's the School of Medicine said: "We are delighted that Evgen will support our plans to undertake a clinical trial on SFX-01 in patients with NASH. Oxidative stress is pivotal to the development of NASH and our research suggests that activation of the Nrf2 pathway, which in turn reduces oxidative stress, can reverse the pathology."

6/2/20

University of Manchester collaboration discovery

Gene signature identified which may determine response to SFX-01 in ER+ breast cancer treatment

Evgen closer to predicting which patients are most likely to benefit from breast cancer drug

Steve Franklin, CEO of Evgen Pharma, said: "This latest data from an eight-year collaboration with Manchester University, and the forthcoming publication, are very positive developments for both the design of future clinical trials and for supporting business development activity with potential partners. The University of Manchester have been tremendous collaborators and we would like to thank them for their continued commitment and enthusiasm.

13/2/20

University of Rochester Collaboration

Evgen Pharma (Evgen) and The University of Rochester School of Medicine and Dentistry have entered into a Memorandum of Understanding to advance SFX-01 towards a clinical trial in chronic kidney disease (CKD).

Thu Le, Professor of Medicine, and Chief of the Division of Nephrology at the University of Rochester Medical Center said: "We are pleased that Evgen will support our plans to undertake a clinical trial on SFX-01 in patients with CKD. Increased oxidative stress is a major molecular underpinning of CKD progression and our research suggests that patients with the GSTM1 null allele may particularly benefit from sulforaphane treatment via SFX-01 dosing."

Dr Stephen Franklin, CEO of Evgen Pharma, commented:

"We are delighted to be supporting the work of such a respected team and prestigious university. We very much hope the proposed trial will generate data demonstrating that SFX-01 could potentially improve the lives of patients suffering from CKD."

[moneymunch] 05/5/2020 18:25

Therapeutic Solutions International Leverages Filed and Issued Intellectual Property to Develop COVID-19 Nutraceutical Candidate: QuadraMune™

Published: May 05, 2020


OCEANSIDE, California, May 5, 2020 /PRNewswire/ -- Therapeutics Solutions International, Inc., (OTC Markets: TSOI) announced the filing of a patent application covering QuadraMune™, a nutraceutical developed to address issues of susceptibility, inflammation, and viral immunity, for COVID-19 patients.

.....................

"QuadraMune, as the name applies, consists of four unique ingredients that in tandem provide synergism in reducing inflammation," said Tim Dixon, President, and CEO of TSOI and co-inventor of the patent. "We have of course included pterostilbene, a very potent inhibitor of inflammatory molecules, along with sulforaphane, a phase II detox promoter which also protects lungs from damage by activating the Nrf2 gene [9], EGCg (epigallocatechin gallate), extracted from green tea that can stimulate T cells [10], inhibit pathological immunity [11], and also protect the lungs, and thymoquinone which comes from the plant nigella sativa that suppresses autophagy, potential antiviral mechanistic effects on cells [12], and has been demonstrated to stimulate NK cells [13] which are antiviral."

[moneymunch] 05/5/2020 18:21

• September 05 2019: Memorandum of Understanding penned with Guy's and St Thomas' NHS Foundation Trust to supply SFX-01 to support a clinical trial in patients diagnosed with Autism Spectrum Disorder (ASD). There are currently no approved medicines for treating the three core symptoms of autism (communication difficulties, social challenges and repetitive behaviour) which have long represented a huge area of unmet clinical need for affected families. Based on its novel mode-of-action, SFX-01 has the potential to become a first-in-class treatment for the core symptoms of ASD, disrupting the current £3bn ASD market.

.......................................

Published: 02 April 2020

Biomarker Exploration in Human Peripheral Blood Mononuclear Cells for Monitoring Sulforaphane Treatment Responses in Autism Spectrum Disorder

[moneymunch] 05/5/2020 18:05

ps a couple of nice 125k and 150k delayed buys at close, both at 12.5p all bodes well. Gla ;-)

[moneymunch] 05/5/2020 17:59

Lol, your first post on EVG, are you sure you're in??? ;-)

[alaneagle] 05/5/2020 17:19

New CEO - Then Major funding - odds on after Spike. I'm Out.

[alaneagle] 05/5/2020 17:19

New CEO - Then Major funding - odds on after Spike. I'm Out.

[moneymunch] 05/5/2020 09:59

News coming soon.Gl :-)

[toffeeman] 05/5/2020 09:43

Looks on to close that gap but not counting chickens!

[moneymunch] 05/5/2020 08:33

Looking good and strong...Gla ;-)